Kaeberlein on why rapamycin trials in Alzheimer's are scarce
Thumbnail from YouTube. Playing loads the YouTube player.
History & recommendationsOff
Keep recently viewed content on this browser. Your history stays on this device and is never sent to Harbor. Videos you play can also help order related video recommendations.
Open saved items & history →At a glance
Automatic summary · not editorially reviewedIn this video description, Dr. Matt Kaeberlein says Alzheimer's research has not prioritized biological aging, which he calls the disease's primary risk factor, and links the lack of rapamycin trials to funding and reputational barriers. [1]
Kaeberlein argues that Alzheimer's research has not prioritized biological aging, which he calls the disease's primary risk factor. [1]
He attributes the lack of rapamycin trials in Alzheimer's to a lack of financial incentive because rapamycin is generic and to reputational barriers from its history as an immunosuppressant. [1]
He notes that interest in aging biology is gradually increasing within the biomedical field. [1]
Kaeberlein's claim on aging as Alzheimer's risk factor
According to the description, Dr. Matt Kaeberlein argues that the Alzheimer's research community has failed to prioritize biological aging. He identifies biological aging as the primary risk factor for the disease. The description presents this as his position, not as a result of a study reported here. [1]
Why Kaeberlein sees few rapamycin trials in Alzheimer's
The description says he attributes the lack of clinical trials of rapamycin in this context to two barriers. One is a lack of financial incentive because rapamycin is generic. The other is reputational, stemming from its history as an immunosuppressant. These are his stated explanations for the trial gap, not evidence that rapamycin works against Alzheimer's disease. [1]
Growing interest in aging biology, per the description
Despite these challenges, the description notes that he sees interest in aging biology gradually increasing within the biomedical field. The description does not report trial results, participant numbers, outcomes or a study design. It also does not establish that rapamycin prevents or treats Alzheimer's disease in humans. [1]
Context & limits
This is based only on the video description. The video and transcript were not reviewed, and no trial results, sample sizes or outcomes are reported. The statements are attributed to the speaker, not established findings.
Based on the creator’s description; the full video and transcript were not analyzed.
Quoted passages in the original language
primary risk factor for the disease
lack of financial incentive due to its
interest in aging biology is gradually increasing
About this video
Creator description · original language
Diagnostic Detectives Network · 9 min · Source published: 2026-09-25
Added to Harbor: 10/22/2026
Original on YouTube ↗Automatically categorized source. Creator statements are not an independent evidence review or personal medical guidance.